NEAT1 and Miyoshi myopathy: As shown in Table 1, there was no significant difference in relative level of NEAT1 in PBMC between the 60 MM patients in terms of gender, age, immunoglobulin subtype, treatment regimens and while the correlation between NEAT1 expression and cytogenetic was estimated too weak to influence the usefulness of lncRNA NEAT1 as biomarkers for MM (all P > 0.05).